Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared The Lancet, New Scientist, and Oncology Nurse Advisor.

Most Recent Articles by Bryant Furlow

Paths Forward for Confronting Extramedullary Multiple Myeloma

Paths Forward for Confronting Extramedullary Multiple Myeloma

By

Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.

CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

By

Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.

An Uncertain Future for Durvalumab in Lung Cancer Management

An Uncertain Future for Durvalumab in Lung Cancer Management

By

Durvalumab's optimal clinical role in managing lung cancer remains unclear and more robust predictive biomarkers are needed.

Follicular Lymphoma: CT-P10, GP2013 Are Biosimilar to Rituximab

Follicular Lymphoma: CT-P10, GP2013 Are Biosimilar to Rituximab

By

CT-P10 and GP2013 exhibit non-inferior overall response efficacy and equivalent pharmacokinetics to rituximab among patients with advanced follicular lymphoma.

Mantle Cell Lymphoma: Evaluating the Treatment Landscape

Mantle Cell Lymphoma: Evaluating the Treatment Landscape

By

Relapse is inevitable in mantle cell lymphoma. Treatment of relapsed MCL is, however, evolving, with several treatment regimen options, though ibrutinib is still the standard of care.

More Articles by Bryant Furlow

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters